Verum.de
, a full-clinical service, German-based contract research organization (CRO) with a new office in Carlsbad, Calif., has entered into an agreement with the
Center for Oncologic Diagnosis and Treatment
(Oncocard) in Romania to be its preferred provider of clinical trial services. The center, developed with the first private investment funding in oncology in Romania, is brand new and features state-of-the-art services and equipment. The center selected Verum.de as their CRO of choice so they could assist with
running clinical trials
and offer patients all possible treatment options.
“The esteemed medical professionals involved with the center provide patients a sophisticated level of treatment and services that are rare for the area,” stated Verum’s local Romanian Medical Director Laurentiu Nedelcu, a doctor and pharmacologist who has supervised Verum trials since 1996. “Verum is known for its
regional expertise
, and we’re pleased to be the CRO the center has chosen to work with.”
The
Oncology Center
, which opened in June, 2012, is a 86,112 sq. feet clinic offering full spectrum oncologic chemotherapy, radiotherapy, treatment of hematological malignancies
and surgical services to patients in addition to serving as an investigative center for research. The Oncology Center’s medical staff is highly qualified and many of the Oncology Center’s staff doctors have experience working with Verum. To date, more than 1,700 patients have been treated at the facility and more than 3,800 investigations have been performed.
“The center was opened to offer a higher level of care to cancer patients, with the best services and equipment modern medicine has available,” explained the center’s Medical Director, Dr. Mihai Ciochinaru. “We trust working with a CRO such as Verum, which runs trials in an efficient, highly ethical manner and understands the region.”
Verum provides
clinical trial services
with Western standards in Central and Eastern European countries (CEE) and former Soviet bloc countries. Verum recently opened a U.S. office in Carlsbad to assist U.S. clients with international trials, and the
new office
is headed by Kristi Clark, an industry veteran with more than 20 years of pharma and biotech experience in both large and mid-size CROs.
Related Links:How CROs Help Oncology Sponsors Produce Results
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.